Literature DB >> 11679986

Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study.

J Figueras1, L Ibañez, E Ramos, E Jaurrieta, J Ortiz-de-Urbina, F Pardo, J Mir, C Loinaz, L Herrera, P López-Cillero, J Santoyo.   

Abstract

Orthotopic liver transplantation (OLT) offers the only chance to eliminate both tumor and liver disease in patients with hepatocellular carcinoma (HCC) and cirrhosis. However, tumor progression while on the waiting list and recurrence after OLT are frequent. We undertook a large multicenter study to assess survival and related factors of recurrence after OLT. This retrospective study analyses data from 307 consecutive patients with HCC and cirrhosis treated with OLT between 1990 and 1997 in eight centers in Spain. OLT was indicated only for small (<5 cm) localized tumors. Five-year rates after OLT were 63% for survival, 58% for disease-free survival, and 21% for recurrence. Tumor diameter larger than 5 cm was associated with other tumor characteristics that were significant indicators of poor outcome (absence of capsule, three or more nodules, bilobularity, satellite nodules, and vascular invasion). However, in multivariate analysis, alpha fetoprotein (AFP) levels greater than 300 ng/mL (P = .04; P = .02) and macroscopic vascular invasion (P = .01; P = .0001) were the only factors independently associated with mortality and recurrence, respectively. OLT is indicated in patients with small HCCs who have low AFP levels and no macroscopic vascular invasion or extrahepatic disease. By increasing our ability for preoperative tumor imaging, we will achieve better selection of patients with HCC before OLT.

Entities:  

Mesh:

Year:  2001        PMID: 11679986     DOI: 10.1053/jlts.2001.27856

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  39 in total

1.  Current management of patients with hepatocellular carcinoma.

Authors:  Tatsuo Kanda; Sadahisa Ogasawara; Tetsuhiro Chiba; Yuki Haga; Masao Omata; Osamu Yokosuka
Journal:  World J Hepatol       Date:  2015-07-28

2.  Vascular invasion in hepatitis B virus-related hepatocellular carcinoma with underlying cirrhosis: possible associations with ascites and hepatitis B viral factors?

Authors:  Chuan Chen; Dong-Ping Chen; Yan-Yan Gu; Liang-Hao Hu; Dan Wang; Jin-Huan Lin; Zhao-Shen Li; Jing Xu; Ge Wang
Journal:  Tumour Biol       Date:  2015-04-02

3.  Current status of therapy for hepatocellular carcinoma.

Authors:  Kathleen E Corey; Daniel S Pratt
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

Review 4.  Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop.

Authors:  Kymberly D S Watt; Kelly Burak; Marc Deschênes; Les Lilly; Denis Marleau; Paul Marotta; Andrew Mason; Kevork M Peltekian; Eberhard L Renner; Eric M Yoshida
Journal:  Can J Gastroenterol       Date:  2006-11       Impact factor: 3.522

5.  Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation.

Authors:  Kathy Han; George N Tzimas; Jeffrey S Barkun; Peter Metrakos; Jean L Tchervenkov; Nir Hilzenrat; Phil Wong; Marc Deschênes
Journal:  Can J Gastroenterol       Date:  2007-01       Impact factor: 3.522

6.  Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma.

Authors:  Fabrice Muscari; Jean-Pascal Guinard; Nassim Kamar; Jean-Marie Peron; Philippe Otal; Bertrand Suc
Journal:  World J Surg       Date:  2012-08       Impact factor: 3.352

7.  Resection or transplant-listing for solitary hepatitis C-associated hepatocellular carcinoma: an intention-to-treat analysis.

Authors:  Hiroshi Sogawa; Brian Shrager; Ghalib Jibara; Parissa Tabrizian; Sasan Roayaie; Myron Schwartz
Journal:  HPB (Oxford)       Date:  2012-08-30       Impact factor: 3.647

Review 8.  Tumor thrombus: incidence, imaging, prognosis and treatment.

Authors:  Keith Bertram Quencer; Tamir Friedman; Rahul Sheth; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

9.  The value of serum alpha-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma.

Authors:  Xiao Xu; Qing-Hong Ke; Zhe-Xin Shao; Jian Wu; Jun Chen; Lin Zhou; Shu-Sen Zheng
Journal:  Dig Dis Sci       Date:  2008-06-18       Impact factor: 3.199

10.  Inclusion of tumor markers improves the correlation of the Milan criteria with vascular invasion and tumor cell differentiation in patients with hepatocellular carcinoma undergoing liver resection (#JGSU-D-07-00462).

Authors:  Kiyoshi Hasegawa; Hiroshi Imamura; Masayoshi Ijichi; Yutaka Matsuyama; Keiji Sano; Yasuhiko Sugawara; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  J Gastrointest Surg       Date:  2008-01-18       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.